|
| |
A vertically-integrated
pharma company |
What We Are |
|
Dr Reddy’s is a global, vertically integrated pharmaceutical company with a presence across the value chain, producing and delivering safe, innovative, and high quality finished dosage forms, active pharmaceutical ingredients and biological products. Our products are marketed across the globe, with an emphasis on North America, Europe, India, Russia and other emerging markets. We conduct NCE drug discovery research in the areas of metabolic disorders and cardiovascular indications at our research facilities in Atlanta (USA) and Hyderabad (India). Through our Custom Pharmaceutical Services business unit, we provide drug substance and drug product development and manufacturing services on a proprietary basis. |
| PHARMACEUTICAL CHEMICALS |
| Active Pharmaceutical Ingredients (API) |
Our capabilities span 24 major chemistries including stereo-selective synthesis, cryogenics, hydrogenations and cyanations. Our strong IP, Regulatory and Analytical skills are evident in the 84 US DMFs we have filed, the highest in India and second highest in the world. Our manufacturing facilities are capable of supporting the product development effort through the concurrent scale-up and piloting of feasible routes as they are developed by the R&D teams. State-of-the-art equipment and instruments give us the edge to compete globally. Our operations are fully integrated through supply-chain and ERP systems (SAP R/3), which enable seamless response to customers, all the while keeping the environment around our plants clean, green and safe. |
 |
|
| Custom Pharmaceutical Services |
 |
In an industry cluttered with chemical manufacturers, CPS stands out because of our understanding of the pharmaceutical business and the associated expertise needed. Rather than just being a chemical provider, CPS offers a service mix covering the entire pharmaceutical value chain. We execute cost-effective and time-bound projects for our customers, and provide them with cGMP-compliant products manufactured in FDA-inspected, ISO-certified facilities. A team of experienced project managers ensures smooth progress of projects from initiation to closure in order to avoid any cost and time overruns.
|
|
| GENERICS |
Generic Formulations
Geographic diversification, cost containment, strengthening our product portfolio and building scale – we at Dr. Reddy’s are strong in all these aspects in the generics space. We are now the fourth largest player in Germany after the acquisition of betapharm, and are constantly looking for opportunities to maximize the potential of our current and future portfolio in different territories across the US and EU. We have the necessary expertise for customer-specific packaging, compliance packaging, and anti-counterfeit packaging. In fact, Dr. Reddy’s has won several awards globally for our packaging efforts, including the Asia Star, AmeriStar and WorldStar awards.
|
 |
|
Branded Formulations |
 |
Dr. Reddy’s brands are today recognized and trusted across several continents. Brands like Omez (Omeprazole), Nise (Nimesulide), Stamlo (Amlodipine), Ciprolet (Ciprofloxacin), Enam (Enalapril) and Ketorol (Ketorolac) are leaders in their category in several countries, with many of them being used by more patients than use the innovator’s product. Over 1.5 million patients across the world take ‘Omez’ for their acid peptic disorders every single day! Entrepreneurship, coupled with the will to make a difference drives our 2,000-strong field force to reach out to over 210,000 doctors and 115,000 pharmacies in more than 40 countries across the world.
|
|
| INNOVATION |
| Discovery Research |
We have put in place a state-of-the-art, fully-integrated discovery infrastructure to strengthen our effort to discover and develop therapeutically useful New Chemical Entities (NCEs) and market them globally. Our two Discovery Research centers – one in Atlanta, USA, and the other in Hyderabad, India, have more than 300 scientists actively involved in a number of drug-discovery and clinical development programs. |
 |
|
| Specialty Pharmaceuticals |
 |
Our Specialty Pharmaceuticals business deals with assets like acquired proprietary technologies, internally developed proprietary drug-delivery platforms, and current internal compounds under pre-clinical and clinical development. Our initial global therapeutic area focus is on dermatology and oncology, two therapeutic areas that best leverage our internal assets. A key component of the strategy in this area is a strong, targeted business development effort to accelerate market entry. |
|
| Biopharmaceuticals |
Our Biologics Development Center spans an area of 36,000 sq. ft., with development and manufacturing suites for both E. coli and mammalian cell culture. It caters to the highest development standards of cGMP, GLP and applicable levels of bio-safety. Grafeel (Filgrastim), our first biologics product to enter the market, enjoys a market share of almost 50% in India and has been able to reach many more patients than the innovator’s product due to its affordability. Our second product Reditux (Rituximab) is the first biosimilar monoclonal antibody to be developed and launched anywhere in the world.
|
 |
|
|
|
|
|
